BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25735355)

  • 1. Hypermethylation of TET1 promoter is a new diagnosic marker for breast cancer metastasis.
    Sang Y; Cheng C; Tang XF; Zhang MF; Lv XB
    Asian Pac J Cancer Prev; 2015; 16(3):1197-200. PubMed ID: 25735355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
    Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
    Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases.
    Hsu CH; Peng KL; Kang ML; Chen YR; Yang YC; Tsai CH; Chu CS; Jeng YM; Chen YT; Lin FM; Huang HD; Lu YY; Teng YC; Lin ST; Lin RK; Tang FM; Lee SB; Hsu HM; Yu JC; Hsiao PW; Juan LJ
    Cell Rep; 2012 Sep; 2(3):568-79. PubMed ID: 22999938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,6-Dihydroxyflavone regulates microRNA-34a through DNA methylation.
    Peng X; Chang H; Chen J; Zhang Q; Yu X; Mi M
    BMC Cancer; 2017 Sep; 17(1):619. PubMed ID: 28870206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer.
    Kang S; Kim B; Park SB; Jeong G; Kang HS; Liu R; Kim SJ
    Int J Oncol; 2013 Nov; 43(5):1659-65. PubMed ID: 24026393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway.
    Neri F; Dettori D; Incarnato D; Krepelova A; Rapelli S; Maldotti M; Parlato C; Paliogiannis P; Oliviero S
    Oncogene; 2015 Aug; 34(32):4168-76. PubMed ID: 25362856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer.
    Thomson JP; Ottaviano R; Unterberger EB; Lempiäinen H; Muller A; Terranova R; Illingworth RS; Webb S; Kerr AR; Lyall MJ; Drake AJ; Wolf CR; Moggs JG; Schwarz M; Meehan RR
    Cancer Res; 2016 May; 76(10):3097-108. PubMed ID: 27197233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3'-shore.
    Park JL; Kim HJ; Seo EH; Kwon OH; Lim B; Kim M; Kim SY; Song KS; Kang GH; Kim HJ; Choi BY; Kim YS
    Oncotarget; 2015 Nov; 6(35):37647-62. PubMed ID: 26462176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis.
    Sun M; Song CX; Huang H; Frankenberger CA; Sankarasharma D; Gomes S; Chen P; Chen J; Chada KK; He C; Rosner MR
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9920-5. PubMed ID: 23716660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mono-ADP-ribosylation of H3R117 traps 5mC hydroxylase TET1 to impair demethylation of tumor suppressor gene TFPI2.
    Li M; Tang Y; Li Q; Xiao M; Yang Y; Wang Y
    Oncogene; 2019 May; 38(18):3488-3503. PubMed ID: 30651599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypermethylation of syk gene in promoter region is associated with oncogenesis, metastasis of breast carcinoma].
    Ding YB; Wu ZY; Wang S; Zha XM; Zheng W; Liu XA; Fan P
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):290-3. PubMed ID: 15059510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers.
    Li L; Li C; Mao H; Du Z; Chan WY; Murray P; Luo B; Chan AT; Mok TS; Chan FK; Ambinder RF; Tao Q
    Sci Rep; 2016 May; 6():26591. PubMed ID: 27225590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia Drives Breast Tumor Malignancy through a TET-TNFα-p38-MAPK Signaling Axis.
    Wu MZ; Chen SF; Nieh S; Benner C; Ger LP; Jan CI; Ma L; Chen CH; Hishida T; Chang HT; Lin YS; Montserrat N; Gascon P; Sancho-Martinez I; Izpisua Belmonte JC
    Cancer Res; 2015 Sep; 75(18):3912-24. PubMed ID: 26294212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-520b suppresses proliferation of hepatoma cells through targeting ten-eleven translocation 1 (TET1) mRNA.
    Zhang W; Lu Z; Gao Y; Ye L; Song T; Zhang X
    Biochem Biophys Res Commun; 2015 May; 460(3):793-8. PubMed ID: 25824049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putative promoters within gene bodies control exon expression via TET1-mediated H3K36 methylation.
    Ma L; Muhammad T; Wang H; Du G; Sakhawat A; Wei Y; Ali Khan A; Cong X; Huang Y
    J Cell Physiol; 2020 Oct; 235(10):6711-6724. PubMed ID: 31994732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of BRCA1 promoter hypermethylation in Thai breast cancer patients.
    Saelee P; Chaiwerawattana A; Ogawa K; Cho YM; Tiwawech D; Suktangman V
    Asian Pac J Cancer Prev; 2014; 15(24):10585-9. PubMed ID: 25605143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel prognostic marker in invasive breast cancer. ITIH5 expression is abrogated by aberrant promoter methylation].
    Veeck J; Breuer E; Rose M; Chorovicer M; Naami A; Bektas N; Alkaya S; von Serényi S; Horn F; Hartmann A; Knüchel R; Dahl E
    Pathologe; 2008 Nov; 29 Suppl 2():338-46. PubMed ID: 18810445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methyl-CpG Binding Domain Protein 2 Inhibits the Malignant Characteristic of Lung Adenocarcinoma through the Epigenetic Modulation of 10 to 11 Translocation 1 and miR-200s.
    Pei YF; Xu XN; Wang ZF; Wang FW; Wu WD; Geng JF; Liu XQ
    Am J Pathol; 2019 May; 189(5):1065-1076. PubMed ID: 30735628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.